Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.isci.2020.100868
DC FieldValue
dc.titleComprehensive Proteomic Characterization Reveals Subclass-Specific Molecular Aberrations within Triple-negative Breast Cancer
dc.contributor.authorKosok, M.
dc.contributor.authorAlli-Shaik, A.
dc.contributor.authorBay, B.H.
dc.contributor.authorGunaratne, J.
dc.date.accessioned2021-08-23T03:14:14Z
dc.date.available2021-08-23T03:14:14Z
dc.date.issued2020-02-21
dc.identifier.citationKosok, M., Alli-Shaik, A., Bay, B.H., Gunaratne, J. (2020-02-21). Comprehensive Proteomic Characterization Reveals Subclass-Specific Molecular Aberrations within Triple-negative Breast Cancer. iScience 23 (2) : 100868. ScholarBank@NUS Repository. https://doi.org/10.1016/j.isci.2020.100868
dc.identifier.issn25890042
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/198621
dc.description.abstractTriple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer lacking targeted therapies. This is attributed to its high heterogeneity that complicates elucidation of its molecular aberrations. Here, we report identification of specific proteome expression profiles pertaining to two TNBC subclasses, basal A and basal B, through in-depth proteomics analysis of breast cancer cells. We observed that kinases and proteases displayed unique expression patterns within the subclasses. Systematic analyses of protein-protein interaction and co-regulation networks of these kinases and proteases unraveled dysregulated pathways and plausible targets for each TNBC subclass. Among these, we identified kinases AXL, PEAK1, and TGFBR2 and proteases FAP, UCHL1, and MMP2/14 as specific targets for basal B subclass, which represents the more aggressive TNBC cell lines. Our study highlights intricate mechanisms and distinct targets within TNBC and emphasizes that these have to be exploited in a subclass-specific manner rather than a one-for-all TNBC therapy. © 2020 The AuthorsBiological Sciences; Cancer Systems Biology; Cancer; Proteomics © 2020 The Authors
dc.publisherElsevier Inc.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScopus OA2020
dc.subjectBiological Sciences
dc.subjectCancer
dc.subjectCancer Systems Biology
dc.subjectProteomics
dc.typeArticle
dc.contributor.departmentMECHANOBIOLOGY INSTITUTE
dc.contributor.departmentANATOMY
dc.description.doi10.1016/j.isci.2020.100868
dc.description.sourcetitleiScience
dc.description.volume23
dc.description.issue2
dc.description.page100868
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1016_j_isci_2020_100868.pdf8.43 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons